Prognostic features of asymptomatic multiple myeloma

Approximately 20% of patients with multiple myeloma are recognized by chance without significant symptoms. In order to prevent morbidity with timely therapy, reliable criteria are needed that distinguish those likely to show early or late disease progression. Multiple clinical features were assessed...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1997-06, Vol.97 (4), p.810-814
Main Authors: Weber, Donna M., Dimopoulos, Meletios A., Moulopoulos, Lia A., Delasalle, Kay B., Smith, Terry, Alexanian, Raymond
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
asymptomatic
Bence Jones Protein - analysis
Biological and medical sciences
Disease Progression
Hematologic and hematopoietic diseases
Humans
Immunoglobulin A - blood
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Magnetic Resonance Imaging
Medical sciences
Middle Aged
multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Myeloma Proteins - analysis
prognosis
survival
Survival Analysis
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Approximately 20% of patients with multiple myeloma are recognized by chance without significant symptoms. In order to prevent morbidity with timely therapy, reliable criteria are needed that distinguish those likely to show early or late disease progression. Multiple clinical features were assessed in 101 consecutive, asymptomatic and previously untreated patients. Patients with one or more lytic bone lesions were excluded because this feature had been found previously to be associated with early progression. Multivariate analysis indicated that only serum myeloma globulin >30 g/l, IgA protein type, and Bence Jones protein excretion >50 mg/d remained as significant independent variables. The presence of two or more of these features signified high‐risk disease with early progression (median 17 months) whereas the absence of any adverse variable was associated with prolonged stability (median 95 months) (P 
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1997.1122939.x